European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
Annals of the Rheumatic Diseases, ISSN: 0003-4967, Vol: 71, Issue: 1, Page: 4-12
2012
- 407Citations
- 305Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations407
- Citation Indexes385
- 385
- CrossRef349
- Clinical Citations11
- PubMed Guidelines11
- Policy Citations11
- Policy Citation11
- Captures305
- Readers305
- 302
Review Description
Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0003496724190073; http://dx.doi.org/10.1136/annrheumdis-2011-200350; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=82955236087&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/21953336; https://linkinghub.elsevier.com/retrieve/pii/S0003496724190073; https://dx.doi.org/10.1136/annrheumdis-2011-200350; https://ard.bmj.com/content/71/1/4; http://ard.bmj.com/content/71/1/4.long; https://ard.bmj.com/content/71/1/4.abstract; https://ard.bmj.com/content/71/1/4.full.pdf; https://ohsu.pure.elsevier.com/en/publications/da38d0d3-426f-460c-b21b-288af1476cf4; https://ard.bmj.com/content/annrheumdis/71/1/4.full.pdf; http://ard.bmj.com/cgi/doi/10.1136/annrheumdis-2011-200350; http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2011-200350; http://ard.bmj.com/content/71/1/4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know